InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,623.06
(
1.17%
)
Post# of 251707
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119567
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: floblu14 post# 83528

Thursday, 02/24/2011 2:59:32 PM

Thursday, February 24, 2011 2:59:32 PM

Post# of 251707
Copaxone was mentioned in passing on MYL’s 4Q10 CC today.* COO Heather Bresch confirmed that the 30-month Hatch-Waxman stay on MYL’s Paragraph-IV challenge runs out in Mar 2012. We already knew this date by simple arithmetic insofar as the FDA accepted MYL’s Copaxone ANDA for review in Sep 2009 (#msg-41441618), when MYL notified Teva of the Paragraph-IV challenge triggering the start of the 30-month clock.

MYL’s 4Q10 PR:
http://investor.mylan.com/releasedetail.cfm?ReleaseID=552326

MYL’s 4Q10 CC slides:
http://investor.mylan.com/common/download/download.cfm?companyid=ABEA-2LQZGT&fileid=443927&filekey=b7c8185d-6856-4463-8eba-e44efdc2b43e&filename=MYLAN%20Q4%202010%2002._24_2011.pdf

*The reference was so fleeting I missed it on the first listen.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up